Cargando…

Should “on-demand” treatments for Parkinson’s disease OFF episodes be used earlier?

We discuss a shift in the treatment paradigm for OFF episode management in patients with Parkinson’s disease, based on clinical experience in the United States (US). Three “on-demand” treatments are currently available in the US as follows: subcutaneous apomorphine, levodopa inhalation powder, and s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Isaacson, Stuart H., Pagan, Fernando L., Lew, Mark F., Pahwa, Rajesh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405081/ https://www.ncbi.nlm.nih.gov/pubmed/36033905 http://dx.doi.org/10.1016/j.prdoa.2022.100161

Ejemplares similares

Istradefylline for OFF Episodes in Parkinson’s Disease: A US Perspective of Common Clinical Scenarios
por: Isaacson, Stuart H, et al.
Publicado: (2022)

Clinical Use of On-Demand Therapies for Patients with Parkinson’s Disease and OFF Periods
por: Pahwa, Rajesh, et al.
Publicado: (2023)

Expert Consensus on the Use of On‐Demand Treatments for OFF Episodes in Parkinson's Disease: A Modified Delphi Panel
por: Isaacson, Stuart H., et al.
Publicado: (2023)

Screening, Diagnosis, and Management of Parkinson’s Disease Psychosis: Recommendations From an Expert Panel
por: Pahwa, Rajesh, et al.
Publicado: (2022)

Correction to: Screening, Diagnosis, and Management of Parkinson’s Disease Psychosis: Recommendations From an Expert Panel
por: Pahwa, Rajesh, et al.
Publicado: (2023)

Apomorphine Subcutaneous Injection for the Management of Morning Akinesia in Parkinson's Disease
por: Isaacson, Stuart, et al.
Publicado: (2016)

Feasibility of home dose optimization of apomorphine sublingual film in Parkinson’s disease patients with OFF episodes: results from the dose-optimization phase of an open-label, randomized crossover study
por: Kassubek, Jan, et al.
Publicado: (2023)

Cost-Effectiveness of Apomorphine Sublingual Film as an “On-Demand” Treatment for “OFF” Episodes in Patients with Parkinson’s Disease
por: Thach, Andrew, et al.
Publicado: (2021)

Dose Optimization of Apomorphine Sublingual Film for OFF Episodes in Parkinson’s Disease: Is the Prophylactic Use of an Antiemetic Necessary?
por: Hauser, Robert A., et al.
Publicado: (2023)

Pupillary Response to Postural Demand in Parkinson’s Disease
por: Kahya, Melike, et al.
Publicado: (2021)

Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment
por: Isaacson, Stuart H., et al.
Publicado: (2023)

Pupillary Response to Cognitive Demand in Parkinson’s Disease: A Pilot Study
por: Kahya, Melike, et al.
Publicado: (2018)

Sialorrhea in Parkinson’s Disease
por: Isaacson, Jonathan, et al.
Publicado: (2020)

Drugs to the Rescue: Comparison of On-Demand Therapies for OFF Symptoms in Parkinson’s Disease
por: Martinez-Nunez, Alfonso E., et al.
Publicado: (2023)

Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson’s Disease and “OFF” Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study
por: Agbo, Felix, et al.
Publicado: (2021)

Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson’s Disease: A Systematic Review and Bayesian Network Meta-analysis
por: Antonini, Angelo, et al.
Publicado: (2022)

Should We Be Screening for Ischaemic Heart Disease Earlier in Childhood?
por: Bassareo, Pier Paolo, et al.
Publicado: (2022)

Non-Invasive Transcutaneous Afferent Patterned Stimulation Therapy Offers Action Tremor Relief in Parkinson’s Disease
por: Brillman, Salima, et al.
Publicado: (2023)

Effective Management of “OFF” Episodes in Parkinson’s Disease: Emerging Treatment Strategies and Unmet Clinical Needs
por: Masood, Nbaa, et al.
Publicado: (2023)

Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesia
por: Pahwa, Rajesh, et al.
Publicado: (2022)

Ulotaront, a Trace Amine-Associated Receptor 1/Serotonin 5-HT(1A) Agonist, in Patients With Parkinson Disease Psychosis: A Pilot Study
por: Isaacson, Stuart H., et al.
Publicado: (2023)

Earlier Intervention with Deep Brain Stimulation for Parkinson's Disease
por: Suarez-Cedeno, Gerson, et al.
Publicado: (2017)

Istradefylline: A novel agent in the treatment of “off” episodes associated with levodopa/carbidopa use in Parkinson disease
por: Cummins, Lauren, et al.
Publicado: (2022)

EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson’s Disease
por: Tanner, Caroline M., et al.
Publicado: (2020)

Istradefylline to Treat Patients with Parkinson’s Disease Experiencing “Off” Episodes: A Comprehensive Review
por: Berger, Amnon A., et al.
Publicado: (2020)

Patient Preferences for Treating “OFF” Episodes in Parkinson’s Disease: A Discrete Choice Experiment
por: Thach, Andrew, et al.
Publicado: (2021)

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study
por: Hauser, Robert A., et al.
Publicado: (2017)

Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study)
por: Pahwa, Rajesh, et al.
Publicado: (2015)

Atherosclerotic Renal Artery Stenosis: Should we Intervene Earlier?
por: de Leeuw, Peter W., et al.
Publicado: (2018)

Evaluation of morning bradykinesia in Parkinson’s disease in a United States cohort using continuous objective monitoring
por: Isaacson, S.H., et al.
Publicado: (2022)

Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open‐label ADS‐5102
por: Isaacson, Stuart H., et al.
Publicado: (2018)

Istradefylline Versus Opicapone for “Off” Episodes in Parkinson’s Disease: A Systematic Review and Meta-Analysis
por: Singh, Alok, et al.
Publicado: (2021)

How to manage the initiation of apomorphine therapy without antiemetic pretreatment: A review of the literature
por: Isaacson, Stuart H., et al.
Publicado: (2022)

An Individualized Multi-Modal Approach for Detection of Medication “Off” Episodes in Parkinson’s Disease via Wearable Sensors
por: Arasteh, Emad, et al.
Publicado: (2023)

Which pathways to psychiatric care lead to earlier treatment and a shorter duration of first-episode psychosis?
por: Bhui, Kamaldeep, et al.
Publicado: (2014)

Randomized, placebo‐controlled trial of ADS‐5102 (amantadine) extended‐release capsules for levodopa‐induced dyskinesia in Parkinson's disease (EASE LID 3)
por: Oertel, Wolfgang, et al.
Publicado: (2017)

A review of ropinirole prolonged release in Parkinson’s disease
por: Nashatizadeh, Muhammad M, et al.
Publicado: (2009)

Cervical Dystonia Resolving After the Onset of Parkinson’s Disease
por: Ortiz, Juan Fernando, et al.
Publicado: (2021)

Recommendations for a paradigm shift in approach to increase the recognition and treatment of sialorrhea in Parkinson’s disease
por: Bergmans, Bruno, et al.
Publicado: (2023)

Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults: A Randomized Clinical Trial
por: Isaacson, Stuart H., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9uh599854lrebe74opktuna3cn